Taxotere, Docetaxel
Taxotere, Docetaxel Newswire (Page 5)

Taxotere, Docetaxel Newswire (Page 5)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 5)

Results 81 - 100 of 2,144 in Taxotere, Docetaxel (generic)

  1. Cancer drugs get a new consumer's guideRead the original story w/Photo

    Jun 23, 2015 | The Maryland Gazette

    A new decision-making tool aims to help oncologists and their patients decide whether the newest -- and more expensive -- cancer regimens are likely to deliver on their promises. A new decision-making tool aims to help oncologists and their patients decide whether the newest -- and more expensive -- cancer regimens are likely to deliver on their promises.

    Comment?

  2. Synta Announces Journal Publication Describing Complementary Activity ...Read the original story

    Jun 22, 2015 | BioSpace

    Synta Pharmaceuticals Corp. today announced the publication in this month's issue of Cancer Immunology Research of an in-depth review describing the rationale for pursuing the combination of Hsp90 and immune checkpoint inhibition for cancer therapy. The review article, titled "Targeting Heat-Shock Protein 90 as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy," is available online at .

    Comment?

  3. BIND Therapeutics Announces FDA Authorization Of First-in-Human...Read the original story

    Jun 22, 2015 | BioSpace

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurinsa , today announced that the U.S. Food and Drug Administration has authorized the use of AstraZeneca's Accurin AZD2811 in clinical trials under an investigational new drug application. BIND is collaborating with AstraZeneca on the development of AZD2811, an Aurora B Kinase inhibitor that has been shown to be active in both solid and hematological tumors in preclinical models, and the companies anticipate enrolling patients in a phase 1 clinical trial with AZD2811 in the fourth quarter of this year.

    Comment?

  4. BIND Therapeutics Appoints Andrew Hirsch as President and Chief Executive OfficerRead the original story

    Jun 22, 2015 | Business Wire

    Mr. Hirsch had been serving in the role on an acting basis since March 2015. Mr. Hirsch has also been elected to BIND's Board of Directors.

    Comment?

  5. Cristal Therapeutics' Proprietary CriPec Nanomedicine Platform And...Read the original story

    Jun 21, 2015 | BioSpace

    Maastricht, The Netherlands, 22 June, 2015 / B3C newswire / -- Cristal Therapeutics, a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases by using its proprietary CriPec platform, today announced the publication of three articles on CriPec -based nanomedicines in Nano Today, Journal of Controlled Release and Biomaterials. The publications are co-authored by Dr. Cristianne Rijcken, founder and CSO of Cristal Therapeutics, and clearly demonstrate the superior therapeutic performance of CriPec nanomedicines in preclinical models as well as the position of the CriPec platform in the overall nanotherapeutics field.

    Comment?

  6. Cristal Therapeutics' Proprietary CriPecA Nanomedicine Platform...Read the original story

    Jun 22, 2015 | B3C

    Maastricht, The Netherlands, 22 June, 2015 / B3C newswire / -- Cristal Therapeutics , a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases by using its proprietary CriPec platform , today announced the publication of three articles on CriPec -based nanomedicines in Nano Today, Journal of Controlled Release and Biomaterials. The publications are co-authored by Dr. Cristianne Rijcken, founder and CSO of Cristal Therapeutics, and clearly demonstrate the superior therapeutic performance of CriPec nanomedicines in preclinical models as well as the position of the CriPec platform in the overall nanotherapeutics field.

    Comment?

  7. Easton Pharmaceuticals And Sign MOU Towards Exclusive Distribution...Read the original story

    Jun 17, 2015 | BioSpace

    Easton Pharmaceuticals Inc. announces it has signed an MOU with BMV Medica SA de CV towards the exclusive distribution for most Latin American countries including Argentina, Chile, Colombia, Peru and Ecuador and all of Central America for a patented Diagnostic Test for the only non-invasive monitoring test for amniotic fluid leaks for women in late-stage pregnancies. The Amniotic Fluid Leak Detection Test -- a valuable new diagnostic test for which Easton / BMV now have the exclusive rights to Latin America, which will enhance Easton / BMV 's franchise and commitment in women's health products.

    Comment?

  8. Celator Pharmaceuticals, Inc. To Present At The Life Sciences Conference 2015Read the original story

    Jun 17, 2015 | BioSpace

    An archived replay of the webcast will be available on the Company's website for 30 days after the conference. , is a clinical stage biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer.

    Comment?

  9. Easton Pharmaceuticals and BMV Medica Sign MOU Towards Exclusive...Read the original story w/Photo

    Jun 18, 2015 | Market Wire

    The Amniotic Fluid Leak Detection Test -- a valuable new diagnostic test for which Easton / BMV now have the exclusive rights to Latin America, which will enhance Easton / BMV 's franchise and commitment in women's health products. Since many countries in the region accept US-FDA approvals with a minimum amount of extra documentation, Easton / BMV could begin selling this new test in these countries pending agreements with local distributors.

    Comment?

  10. BIND Therapeutics to Present at JMP Securities Life Sciences Conference 2015Read the original story

    Jun 16, 2015 | Freshnews

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, announced today that Andrew Hirsch, BIND's president and chief executive officer, will present at the JMP Securities Life Sciences Conference 2015 on Tuesday, June 23, 2015 at 11:30 a.m. ET at the St. Regis hotel in New York City. Interested parties may access a live webcast of the presentation by visiting the BIND Therapeutics website at www.bindtherapeutics.com .

    Comment?

  11. Now Available: BIND Therapeutics, Inc. (BIND) - Pharmaceuticals &...Read the original story

    Jun 15, 2015 | PR-inside.com

    Summary BIND Therapeutics, Inc. is a nanomedicine platform company. The company develops and commercializes preclinical candidates for cancer, cardiovascular disease, and inflammatory disease.

    Comment?

  12. Easton Pharmaceuticals And Close On Joint Distribution Agreement For...Read the original story

    Jun 14, 2015 | BioSpace

    Easton Pharmaceuticals Inc. announces it has closed on the recently announced MOU with BMV Medica S.A. de C.V. to distribute injectable approved cancer drugs from Biolyse Pharma for Mexico and Latin America. The Easton / BMV agreement is under similar terms as previously announced with the Common Sense Inc. agreement for the diagnostic women's health products which maintains a 50/50 net profit sharing on all sales of a line of generic cancer drugs beginning with "Paclitaxel" and "Docetaxel" from St. Catharines, Ontario based Biolyse Pharma Corporation.

    Comment?

  13. "GP Pharm, S.A. - Pharmaceuticals & Healthcare - Deals and Alliances...Read the original story

    Jun 15, 2015 | PR-inside.com

    GP Pharm, S.A. is a pharmaceutical company. It is involved in research, development, production and marketing of injectable products within Urology and Oncology fields.

    Comment?

  14. Study explores role of ALK1 protein in breast cancer metastasisRead the original story w/Photo

    Jun 15, 2015 | Medical News

    Background: Pietras said that although prognosis for breast cancer is relatively good when detected in its early stages, metastatic disease is the cause of 90 percent of all cancer-related deaths. Therefore, learning more about the metastatic process and finding new cures to inhibit disease spread is at the center of clinical attention.

    Comment?

  15. ALK1 protein may play a role in breast cancer metastasisRead the original story

    Jun 15, 2015 | Medical News Today

    Pietras said that although prognosis for breast cancer is relatively good when detected in its early stages, metastatic disease is the cause of 90 percent of all cancer-related deaths. Therefore, learning more about the metastatic process and finding new cures to inhibit disease spread is at the center of clinical attention.

    Comment?

  16. U.S. FDA Reactivates Prescient Therapeutics's IND For PTX-100 Breast Cancer TrialRead the original story

    Jun 9, 2015 | BioSpace

    This follows the acquisition of the drug from Pathway Oncology in mid-2014. This follows a submission to the FDA of a detailed and complete protocol for the proposed study in patients with Stage IV metastatic breast cancer.

    Comment?

  17. Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapyRead the original story w/Photo

    Jun 9, 2015 | Medical News

    In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 respond to chemotherapy just as well as men who lack the variant. The findings, the researchers say, may be significant for patients who carry the AR-V7 variant, because they are more likely to develop resistance to one of two hormone drugs routinely used to treat their disease.

    Comment?

  18. Chemo may be preferred option for some with advanced prostate cancerRead the original story w/Photo

    Jun 9, 2015 | PhysOrg Weblog

    In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 respond to chemotherapy just as well as men who lack the variant. The findings, the researchers say, may be significant for patients who carry the AR-V7 variant, because they are more likely to develop resistance to one of two hormone drugs routinely used to treat their disease.

    Comment?

  19. Chemo Instead of Hormone Therapy May Be Preferred Option for Some with Advanced Prostate CancerRead the original story

    Jun 8, 2015 | Newswise

    In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 respond to chemotherapy just as well as men who lack the variant. The findings, the researchers say, may be significant for patients who carry the AR-V7 variant, because they are more likely to develop resistance to one of two hormone drugs routinely used to treat their disease.

    Comment?

  20. Easton Pharmaceuticals Signs MOU Towards Distributing A Line Of...Read the original story

    Jun 7, 2015 | BioSpace

    Easton Pharmaceuticals Inc. announces it has signed an MOU agreement towards finalizing negotiations with BMV Medica S.A. de C.V. to jointly distribute and sell a line of the most common and used cancer drugs throughout Mexico and most of Latin America. The majority of these sales will be to the Mexican and other national governments through their national tender program.

    Comment?